Contact Us | Disclaimer Privacy Policy | Partners Innovation

© Copyright Partners Innovation Fund

PARTNERS INNOVATION FUND

 

Roche to buy U.S. biotech group Adheron Therapeutics

ZURICH, Oct 9 (Reuters) - Swiss drugmaker Roche will acquire U.S. biotech group Adheron Therapeutics in a deal worth up to $580 million that boosts its pipeline of products to treat diseases such as rheumatoid arthritis, Adheron said on Friday.


California-based Adheron’s technology disrupts immune cell adhesion through a protein called Cadherin-11. Its lead asset, SDP051, is a humanised monoclonal antibody that has completed Phase 1 of clinical development.


Read Full Article Here: https://www.reuters.com/article/roche-ma-adheron/roche-to-buy-u-s-biotech-group-adheron-therapeutics-idUSL8N1292HH20151009